Generics Bulletin Explains: After Humira Biosimilars, Will It Be Groundhog Day For Stelara?

In the 1993 film Groundhog Day, Bill Murray starred as Phil Connors, a man condemned to the repetition of living the same day over and over again. With biosimilar competition to Stelara (ustekinumab) on the horizon, the off-patent industry may be wondering whether to expect a similar fate. The parallels between Stelara and Humira (adalimumab), which has already faced biosimilar competition around the world, are multiple. The two juggernaut immunology biologic brands share a similar profile, while the lead-up to competition for both has seen a framework of legal settlements agreed with the originator – in the case of Stelara, Johnson & Johnson’s Janssen – to allow for market entry around the world.
Author:
Biocon Biologics